![Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial - The Lancet HIV Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/4a278335-b614-45eb-882d-3457c08b7b3b/gr1.gif)
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial - The Lancet HIV
![Biostats Masters Student Jinyi Zhou Receives Poster Award | Duke Department of Biostatistics and Bioinformatics Biostats Masters Student Jinyi Zhou Receives Poster Award | Duke Department of Biostatistics and Bioinformatics](https://biostat.duke.edu/sites/default/files/images/Zhou_poster2020.10.jpg)
Biostats Masters Student Jinyi Zhou Receives Poster Award | Duke Department of Biostatistics and Bioinformatics
![Cancers | Free Full-Text | Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus | HTML Cancers | Free Full-Text | Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus | HTML](https://www.mdpi.com/cancers/cancers-14-04339/article_deploy/html/images/cancers-14-04339-g001.png)
Cancers | Free Full-Text | Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus | HTML
![Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses - ScienceDirect Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S221112472100437X-fx1.jpg)
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses - ScienceDirect
Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study | PLOS ONE
![Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program - Lung Cancer Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/995533/7266587/gr1.jpg)